Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2014-05-15 Regulatory Filings
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
RULE 424(B)(3)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 15, 2014, by Lipocine Inc. It includes a press release announcing Phase 1 clinical study results for LPCN 1107, an oral drug candidate. The document is primarily an update on clinical trial results and does not contain comprehensive financial statements or detailed financial performance data. It is not an earnings release, annual report, or interim report. The document also includes a prospectus supplement related to a registration statement, but the main content is the clinical study announcement. This type of filing is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories such as earnings release, capital update, or management report.
2014-05-15 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it reports the issuance of a press release about Phase 1 clinical study results. The document is short (2242 characters) and primarily serves as an announcement of an event and includes a press release as an exhibit. It does not contain detailed financial statements or comprehensive financial data. Therefore, it is not an Annual Report, Earnings Release, or Interim Report. It is not a certification or officer attestation. The document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2014-05-15 English
RULE 424(B)(3)
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q quarterly report filed with the SEC for the quarterly period ended March 31, 2014. It contains unaudited condensed consolidated financial statements, management's discussion and analysis, notes to financial statements, and other required disclosures typical of a quarterly report. The document length is substantial (15,000 characters), and it includes actual financial data and analysis, not just an announcement or certification. The presence of detailed financial statements and management discussion confirms it is a comprehensive interim financial report. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2014-05-13 English
FORM 10-Q
Interim / Quarterly Report Q1 2014
2014-05-13 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2014-04-29 English
RULE 424(B)(3)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, which includes a press release announcing the completion of enrollment in a Phase 3 clinical trial. The document primarily serves as an update on a clinical trial milestone and does not contain financial statements or detailed financial analysis. It also includes a prospectus supplement related to a registration statement for shares held by selling stockholders, but no new shares are being sold by the company itself. The content is focused on clinical trial progress and related corporate announcements rather than financial results, management changes, or regulatory certifications. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2014-04-29 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.